Back to results
US 2021/0010089 A1Published application
Tumor minimal residual disease stratification
AssigneesVib Vzw, Katholieke Universiteit Leuven, K.U.Leuven R&D
InventorsJean-Christophe Marine, Florian Rambow
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of tumor disease stratification, in particular melanoma disease stratification. In particular it relates to the methods for tumor analysis, such as for determining tumor cell heterogeneity during treatment. These methods are helpful in selecting or optimizing tumor therapy, or in predicting responses to tumor therapy. The invention further relates to methods for screening for cytotoxic or cytostatic compounds targeting one or more of the heterogeneous tumor cell populations occurring such as during therapy, such as during the minimal residual disease phase.
Claims20
A method of analysis of a human tumor, the method comprising detecting in a biological sample from the human tumor or in a biological sample comprising human tumor nucleic acids an increased expression level:
- of one or more genes selected from gene signature A1, wherein gene signature A1 consists of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B;
- and/or
- of one or more genes selected from gene signature A2, wherein gene signature A2 consists of the genes NGFR, GFRA2, GFRA3, RSPO3, L1CAM, AQP1, TMEM176B;
- and/or
- of one or more genes selected from gene selected from gene signature A3, wherein gene signature A3 consists of the genes NGFR, GFRA2, L1CAM, AQP1, TMEM176B;
- and/or
- of one or more genes selected from gene signature B1, wherein gene signature B1 consists of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1;
- and/or
- of one or more genes selected from gene signature B2, wherein gene signature B2 consists of the genes CD36, IP6K3, KIAA1161, TRIM67, LSMEM1, UBXN10, PAX3, SLC7A8;
- and/or
- of one or more genes selected from gene signature B3, wherein gene signature B3 consists of the genes DLX5, CD36, IP6K3, TRIM67, PAX3;
- and/or
- of one or more genes selected from gene signature C1, wherein gene signature C1 consists of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT;
- and/or
- of one or more genes selected from gene signature C2, wherein gene signature C2 consists of the genes GPR143, TYRP1, MLPH, MLANA, TRPM1, EDNRB, PMEL;
- and/or
- of one or more genes selected from gene signature C3, wherein gene signature C3 consists of the genes DCT, MITF, TYR, MLANA, TRPM1;
- and/or
- of one or more genes selected from gene signature D1, wherein gene signature D1 consists of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4;
- and/or
- of one or more genes selected from gene signature D2, wherein gene signature D2 consists of the genes RGS5, SLIT2, AXL, BGN, TGM2, TGFBI, CYR61;
- and/or
- of one or more genes selected from gene signature D3, wherein gene signature D3 consists of the genes WNT5A, AXL, TNC, TCF4, LOXL2, CYR61;
- wherein increased expression level of a selected gene is determined compared to a reference expression level of that selected gene;
- and wherein detection of an increased expression level of a gene selected from any of the gene signatures A1, A2 or A3 is indicating the presence of neural drug tolerant tumor cells (NDTCs), detection of an increased expression level of a gene selected from any of the gene signatures B1, B2 or B3 is indicating the presence of hypometabolic tumor cells (HMTCs), detection of an increased expression level of a gene selected from any of the gene signatures C1, C2 or C3 is indicating the presence of pigmented tumor cells and wherein detection of an increased expression level of a gene selected from any of the gene signatures D1, D2 or D3 is indicating the presence of invasive tumor cells;
- and wherein the detection of the emergence of NDTCs, HMTCs, pigmented tumor cells and/or invasive tumor cells is indicative of a tumor progressing to or being at the minimal residual disease (MRD) phase following anti-tumor therapy.
23 more elements
A method for screening for cytotoxic or cytostatic compounds, the method comprising:
- culturing tumor cells;
- applying a therapy to the cultured tumor cells, wherein the therapy induces the occurrence of one or more populations of tumor cells that are reversibly resistant to the therapy, and wherein the populations are one or more of:
- a population with increased expression of one or more genes selected from gene signature A1, wherein gene signature A1 consists of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B;
- and/or
- a population with increased expression of one or more genes selected from gene signature A2, wherein gene signature A2 consists of the genes NGFR, GFRA2, GFRA3, RSPO3, L1CAM, AQP1, TMEM176B;
- and/or
- a population with increased expression of one or more genes selected from gene selected from gene signature A3, wherein gene signature A3 consists of the genes NGFR, GFRA2, L1CAM, AQP1, TMEM176B;
- and/or
- a population with increased expression of one or more genes selected from gene signature B1, wherein gene signature B1 consists of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1;
- and/or
- a population with increased expression of one or more genes selected from gene signature B2, wherein gene signature B2 consists of the genes CD36, IP6K3, KIAA1161, TRIM67, LSMEM1, UBXN10, PAX3, SLC7A8;
- and/or
- a population with increased expression of one or more genes selected from gene signature B3, wherein gene signature B3 consists of the genes DLX5, CD36, IP6K3, TRIM67, PAX3;
- and/or
- a population with increased expression of one or more genes selected from gene signature C1, wherein gene signature C1 consists of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT;
- and/or
- a population with increased expression of one or more genes selected from gene signature C2, wherein gene signature C2 consists of the genes GPR143, TYRP1, MLPH, MLANA, TRPM1, EDNRB, PMEL;
- and/or
- a population with increased expression of one or more genes selected from gene signature C3, wherein gene signature C3 consists of the genes DCT, MITF, TYR, MLANA, TRPM1;
- and/or
- a population with increased expression of one or more genes selected from gene signature D1, wherein gene signature D1 consists of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI1, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4;
- and/or
- a population with increased expression of one or more genes selected from gene signature D2, wherein gene signature D2 consists of the genes RGS5, SLIT2, AXL, BGN, TGM2, TGFBI, CYR61;
- and/or
- a population with increased expression of one or more genes selected from gene signature D3, wherein gene signature D3 consists of the genes WNT5A, AXL, TNC, TCF4, LOXL2, CYR61;
- wherein the increased expression of a selected gene is determined compared to a reference expression level of the selected gene;
- contacting the one or more populations of tumor cells that are reversibly resistant to the therapy with a compound that is a candidate compound cytotoxic or cytostatic to one or more of the populations of tumor cells that are reversibly resistant to the therapy;
- identifying a compound cytotoxic or cytostatic to one or more of the populations of tumor cells that are reversibly resistant to the therapy.
25 more elements
A method for screening for cytotoxic or cytostatic compounds, the method comprising:
- culturing tumor cells;
- applying a therapy to the cultured tumor cells, wherein the therapy induces the occurrence of one or more populations of tumor cells that are reversibly resistant to the therapy, and wherein the populations are one or more of:
- a population with increased expression of one or more genes selected from gene signature A1, wherein gene signature A1 consists of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B;
- and/or
- a population with increased expression of one or more genes selected from gene signature A2, wherein gene signature A2 consists of the genes NGFR, GFRA2, GFRA3, RSPO3, L1CAM, AQP1, TMEM176B;
- and/or
- a population with increased expression of one or more genes selected from gene selected from gene signature A3, wherein gene signature A3 consists of the genes NGFR, GFRA2, L1CAM, AQP1, TMEM176B;
- and/or
- a population with increased expression of one or more genes selected from gene signature B1, wherein gene signature B1 consists of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1;
- and/or
- a population with increased expression of one or more genes selected from gene signature B2, wherein gene signature B2 consists of the genes CD36, IP6K3, KIAA1161, TRIM67, LSMEM1, UBXN10, PAX3, SLC7A8;
- and/or
- a population with increased expression of one or more genes selected from gene signature B3, wherein gene signature B3 consists of the genes DLX5, CD36, IP6K3, TRIM67, PAX3;
- and/or
- a population with increased expression of one or more genes selected from gene signature C1, wherein gene signature C1 consists of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT;
- and/or
- a population with increased expression of one or more genes selected from gene signature C2, wherein gene signature C2 consists of the genes GPR143, TYRP1, MLPH, MLANA, TRPM1, EDNRB, PMEL;
- and/or
- a population with increased expression of one or more genes selected from gene signature C3, wherein gene signature C3 consists of the genes DCT, MITF, TYR, MLANA, TRPM1;
- and/or
- a population with increased expression of one or more genes selected from gene signature D1, wherein gene signature D1 consists of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI1, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4;
- and/or
- a population with increased expression of one or more genes selected from gene signature D2, wherein gene signature D2 consists of the genes RGS5, SLIT2, AXL, BGN, TGM2, TGFBI, CYR61;
- and/or
- a population with increased expression of one or more genes selected from gene signature D3, wherein gene signature D3 consists of the genes WNT5A, AXL, TNC, TCF4, LOXL2, CYR61;
- wherein the increased expression of a selected gene is determined compared to a reference expression level of the selected gene;
- contacting the one or more populations of tumor cells that are reversibly resistant to the therapy with a compound that is a candidate compound for modifying expression or function of a gene selected from any of gene signatures A1, A2, A3, B1, B2, B3, C1, C2, C3, D1, D2 or D3;
- identifying as cytotoxic or cytostatic compound a compound that is modifying expression or function a gene selected from any of gene signatures A1, A2, A3, B1, B2, B3, C1, C2, C3, D1, D2 or D3.
25 more elements
A compound for use in treating a tumor, in inhibiting tumor progression, in inhibiting tumor relapse, in inhibiting tumor metastasis, in reducing tumor cell heterogeneity in the residual disease phase, or for use in inhibiting acquisition of resistance to a therapy, comprising:
- determining or detecting in a biological sample from the subject having the tumor or in a biological sample comprising human tumor nucleic acids the presence of a cell population with an increased expression level:
- of one or more genes selected from gene signature A1, wherein gene signature A1 consists of the genes AQP1, ITGA1, L1CAM, NLGN3, S100A4, IL1RAP, COL4A1, THBS2, SLITRK6, CADM1, NRXN1, A2M, PRIMA1, GFRA2, MPZ, ADAMTS4, GFRA1, RSPO3, GFRA3, LAMC1, ANXA1, SYT11, MATN2, ATP1B2, ADGB, CNN3, COL1A1, TMEM176B, PLAT, PDGFB, SLC22A17, ITGA6, NGFR, VCAN, ATP1A2, IGF1, SEMA3B;
- and/or
- of one or more genes selected from gene signature A2, wherein gene signature A2 consists of the genes NGFR, GFRA2, GFRA3, RSPO3, L1CAM, AQP1, TMEM176B;
- and/or
- of one or more genes selected from gene signature B1, wherein gene signature B1 consists of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1;
- and/or
- of one or more genes selected from gene selected from gene signature A3, wherein gene signature A3 consists of the genes NGFR, GFRA2, L1CAM, AQP1, TMEM176B;
- and/or
- of one or more genes selected from gene signature B1, wherein gene signature B1 consists of the genes SLC7A8, DLX5, TRIM67, CD36, PAX3, IP6K3, UBXN10, KIAA1161, LSMEM1;
- and/or
- of one or more genes selected from gene signature B2, wherein gene signature B2 consists of the genes CD36, IP6K3, KIAA1161, TRIM67, LSMEM1, UBXN10, PAX3, SLC7A8;
- and/or
- of one or more genes selected from gene signature B3, wherein gene signature B3 consists of the genes DLX5, CD36, IP6K3, TRIM67, PAX3;
- and/or
- of one or more genes selected from gene signature C1, wherein gene signature C1 consists of the genes SLC24A5, PMEL, FABP7, SLC45A2, KIT, EDNRB, TRPM1, APOE, MLANA, MLPH, TYRP1, GPR143, TYR, RAB27A, SNAI2, MITF, DCT;
- and/or
- of one or more genes selected from gene signature C2, wherein gene signature C2 consists of the genes GPR143, TYRP1, MLPH, MLANA, TRPM1, EDNRB, PMEL;
- and/or
- of one or more genes selected from gene signature C3, wherein gene signature C3 consists of the genes DCT, MITF, TYR, MLANA, TRPM1;
- and/or
- of one or more genes selected from gene signature D1, wherein gene signature D1 consists of VCAN, TNC, BCAT1, FOSL2, UNC5B, CCL2, COL1A1, SH2B3, MGP, VEGFA, LOX, FGF1, PDGFRB, IGFBP5, ERRFI1, PRDX1, TGFBI, IL13RA2, SOX4, NES, LOXL2, SPRY2, CDH13, LMO4, RGS5, RGS16, DLX1, SLIT2, GPC3, ADM, EDNRA, CYSLTR2, DDAH1, PLXDC1, VSNL1, COL1A2, DLC1, AXL, ANGPTL4, IGFBP6, COL3A1, FABP4, CDH2, PTGER4, NDNF, NR2F1, BGN, TGM2, TMSB4X, CYR61, WNT5A, TCF4;
- and/or
- of one or more genes selected from gene signature D2, wherein gene signature D2 consists of the genes RGS5, SLIT2, AXL, BGN, TGM2, TGFBI, CYR61;
- and/or
- a population with increased expression of one or more genes selected from gene signature D3, wherein gene signature D3 consists of the genes WNT5A, AXL, TNC, TCF4, LOXL2, CYR61;
- wherein the increased expression of a selected gene is determined compared to a reference expression level of the selected gene;
- and
- administering a therapeutically effective amount of a compound to the subject, wherein the compound is selected to target one or more of the populations detected to be present in the subject, and is chosen from a compound that:
- is cytotoxic or cytostatic for the population of cells in the tumor with, compared to reference expression levels, increased expression levels of the 1 or more genes selected from gene signature A1, A2 or A3, and is chosen from compounds inhibiting, blocking, or antagonizing expression or function of a gene selected from the gene signatures A1, A2 or A3;
- is cytotoxic or cytostatic for the population of cells in the tumor with, compared to reference expression levels, increased expression levels of the 1 or more genes selected from gene signature B1, B2 or B3, and is chosen from compounds inhibiting, blocking, or antagonizing expression or function of a gene selected from the gene signatures B1, B2 or B3;
- is cytotoxic or cytostatic for the population of cells in the tumor with, compared to reference expression levels, increased expression levels of the 1 or more genes selected from gene signature C1, C2 or C3, and is chosen from compounds inhibiting, blocking, or antagonizing expression or function of a gene selected from the gene signatures C1, C2 or C3;
- is cytotoxic or cytostatic for the cells in the tumor with, compared to reference expression levels, increased expression levels of the 1 or more genes selected from gene signature D1, D2 or D3, and is chosen from compounds inhibiting, blocking, or antagonizing expression or function of a gene selected from the gene signatures D1, D2 or D3.
30 more elements
Dependencies are inferred from the claim text.